MitoSciences Involved in Identification of First Possibly Useful Biomarker for Parkinson's Disease

In an article pulished in the May 18th edition of the prestigious Journal of Neuroscience, Dr. Roderick Capaldi, Chief Science Officer of MitoSciences, and his colleagues at the company, as well as at the Universities of Oregon and Virginia, describe the alterations in the mitochondrial oxidative phosphorylation complex, NADH ubiquinone oxidoreductase or, Complex I, that characterize the damaged brain of patients with Parkinson's Disease.

These include subunit alterations and increased oxidative damage to the complex that can be measured readily by technologies developed by MitoSciences. Ongoing work may confirm that these are systemic changes which can be detected in blood or other easily accessible tissues, thereby providing the first biochemical test for this devastating disease.

See The Journal of Neuroscience, May 10, 2006, 26(19):5256-5264.